CORRESP Filing
X4 Pharmaceuticals, Inc
Date: Sept. 15, 2025 · CIK: 0001501697 · Accession: 0001501697-25-000019
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290158
Letter
Document X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4 th Floor Boston, MA 02134 September 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: X4 Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-290158) Ladies and Gentlemen: X4 Pharmaceuticals, Inc. hereby respectfully requests that, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective on September 17, 2025, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. We request that we be notified of such effectiveness by a telephone call to Melanie E. Neary of Gibson, Dunn & Crutcher at (415) 393-8243. Sincerely, X4 PHARMACEUTICALS, INC. By: /s/ David Kirske David Kirske Chief Financial Officer and Treasurer cc: Adam R. Craig, M.D., Ph.D., X4 Pharmaceuticals, Inc. Natasha Thoren, X4 Pharmaceuticals, Inc. Melanie E. Neary, Dunn & Crutcher LLP
Show Raw Text
CORRESP 1 filename1.htm Document X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4 th Floor Boston, MA 02134 September 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: X4 Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-290158) Ladies and Gentlemen: X4 Pharmaceuticals, Inc. hereby respectfully requests that, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective on September 17, 2025, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. We request that we be notified of such effectiveness by a telephone call to Melanie E. Neary of Gibson, Dunn & Crutcher at (415) 393-8243. Sincerely, X4 PHARMACEUTICALS, INC. By: /s/ David Kirske David Kirske Chief Financial Officer and Treasurer cc: Adam R. Craig, M.D., Ph.D., X4 Pharmaceuticals, Inc. Natasha Thoren, X4 Pharmaceuticals, Inc. Melanie E. Neary, Dunn & Crutcher LLP